CLINICAL_TRIALS
trial_result
· 2014-12-18
Clinical Trial Update: Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. [Phase 1]
Summary
A Phase 1 trial evaluating sorafenib-induced hypophosphatemia in renal cell carcinoma has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 1 | Status: TERMINATED